B-intervention	0	13	Perioperative
I-intervention	14	24	Pregabalin
I-intervention	25	28	and
I-intervention	29	43	Intraoperative
I-intervention	44	53	Lidocaine
I-intervention	54	62	Infusion
O	63	65	to
O	66	72	Reduce
B-condition	73	83	Persistent
I-condition	84	95	Neuropathic
I-condition	96	100	Pain
O	101	106	After
O	107	113	Breast
O	114	120	Cancer
O	121	128	Surgery
O	128	129	:
O	130	131	A
O	132	143	Multicenter
O	143	144	,
O	145	154	Factorial
O	154	155	,
O	156	166	Randomized
O	166	167	,
O	168	178	Controlled
O	179	184	Pilot
O	185	190	Trial
O	190	191	.

O	192	202	Persistent
O	203	215	postsurgical
O	216	220	pain
O	221	223	is
O	224	231	defined
O	232	234	as
O	235	239	pain
O	240	249	localized
O	250	252	to
O	253	256	the
O	257	261	area
O	262	264	of
O	265	272	surgery
O	273	275	of
O	276	277	a
O	278	286	duration
O	287	289	of
O	290	291	≥
O	291	292	2
O	293	299	months
O	300	303	and
O	304	306	is
O	306	307	,
O	308	321	unfortunately
O	321	322	,
O	323	324	a
O	325	331	common
O	332	344	complication
O	345	350	after
O	351	357	breast
O	358	364	cancer
O	365	372	surgery
O	372	373	.

O	374	382	Although
O	383	388	there
O	389	391	is
O	392	404	insufficient
O	405	413	evidence
O	414	416	to
O	417	424	support
O	425	428	any
O	429	441	preventative
O	442	450	strategy
O	450	451	,
O	452	457	prior
O	458	468	literature
O	469	477	suggests
O	478	481	the
O	482	490	possible
O	491	499	efficacy
O	500	502	of
O	503	514	intravenous
O	515	524	lidocaine
O	525	528	and
O	529	542	perioperative
O	543	553	pregabalin
O	554	556	in
O	557	567	preventing
O	568	578	persistent
O	579	583	pain
O	584	589	after
O	590	597	surgery
O	597	598	.

O	599	601	To
O	602	611	determine
O	612	623	feasibility
O	624	626	of
O	627	637	conducting
O	638	639	a
O	640	646	larger
O	647	657	definitive
O	658	663	trial
O	663	664	,
O	665	667	we
O	668	677	conducted
O	678	679	a
O	680	691	multicenter
O	692	693	2
O	694	695	×
O	696	697	2
O	698	707	factorial
O	707	708	,
O	709	719	randomized
O	719	720	,
O	721	728	placebo
O	728	729	-
O	729	739	controlled
O	740	745	pilot
O	746	751	trial
O	752	754	of
B-total-participants	755	758	100
B-eligibility	759	765	female
I-eligibility	766	774	patients
I-eligibility	775	785	undergoing
I-eligibility	786	792	breast
I-eligibility	793	799	cancer
I-eligibility	800	807	surgery
O	807	808	.

O	809	817	Patients
O	818	822	were
O	823	833	randomized
O	834	836	to
O	837	844	receive
O	845	847	an
O	848	862	intraoperative
O	863	872	lidocaine
O	873	881	infusion
O	882	883	(
O	883	884	1
O	884	885	.
O	885	886	5
O	887	889	mg
O	889	890	/
O	890	892	kg
O	893	898	bolus
O	899	907	followed
O	908	910	by
O	911	912	2
O	913	915	mg
O	915	916	/
O	916	918	kg
O	918	919	/
O	919	920	h
O	920	921	)
O	922	924	or
B-control	925	932	placebo
O	933	936	and
O	937	950	perioperative
O	951	961	pregabalin
O	962	963	(
O	963	966	300
O	967	969	mg
O	970	984	preoperatively
O	984	985	,
O	986	988	75
O	989	991	mg
O	992	997	twice
O	998	1003	daily
O	1004	1007	for
O	1008	1009	9
O	1010	1014	days
O	1014	1015	)
O	1016	1018	or
O	1019	1026	placebo
O	1026	1027	.

O	1028	1031	All
O	1032	1043	feasibility
O	1044	1052	criteria
O	1053	1057	were
O	1058	1067	surpassed
O	1067	1068	;
O	1069	1080	recruitment
O	1081	1083	of
B-total-participants	1084	1087	100
O	1088	1096	patients
O	1097	1100	was
O	1101	1113	accomplished
O	1114	1120	within
O	1121	1123	42
O	1124	1129	weeks
O	1129	1130	,
O	1131	1135	with
O	1136	1137	a
O	1138	1144	follow
O	1144	1145	-
O	1145	1147	up
O	1148	1152	rate
O	1153	1155	of
O	1156	1159	100
O	1159	1160	%
O	1161	1164	and
O	1165	1170	study
O	1171	1175	drug
O	1176	1186	compliance
O	1187	1189	of
O	1190	1191	≥
O	1191	1193	80
O	1193	1194	%
O	1194	1195	.

O	1196	1198	At
O	1199	1200	3
O	1201	1207	months
O	1207	1208	,
O	1209	1211	53
O	1211	1212	%
O	1213	1215	of
O	1216	1224	patients
O	1225	1233	reported
B-outcome	1234	1244	persistent
I-outcome	1245	1256	neuropathic
I-outcome	1257	1261	pain
O	1261	1262	.

O	1263	1271	Although
O	1272	1277	there
O	1278	1281	was
O	1282	1284	no
O	1285	1296	interaction
O	1297	1304	between
O	1305	1314	lidocaine
O	1315	1318	and
O	1319	1329	pregabalin
O	1329	1330	,
O	1331	1340	lidocaine
O	1341	1350	decreased
O	1351	1354	the
B-outcome	1355	1366	development
I-outcome	1367	1369	of
I-outcome	1370	1380	persistent
I-outcome	1381	1392	neuropathic
I-outcome	1393	1397	pain
O	1398	1399	(
B-iv-bin-percent	1399	1401	43
I-iv-bin-percent	1401	1402	.
I-iv-bin-percent	1402	1403	1
I-iv-bin-percent	1403	1404	%
O	1405	1407	vs
B-cv-bin-percent	1408	1410	63
I-cv-bin-percent	1410	1411	.
I-cv-bin-percent	1411	1412	3
I-cv-bin-percent	1412	1413	%
O	1413	1414	;
O	1415	1423	relative
O	1424	1428	risk
O	1429	1430	=
O	1431	1432	.
O	1432	1434	68
O	1434	1435	;
O	1436	1438	95
O	1438	1439	%
O	1440	1450	confidence
O	1451	1459	interval
O	1460	1461	=
O	1462	1463	.
O	1463	1465	47
O	1465	1466	-
O	1466	1467	1
O	1467	1468	.
O	1468	1469	0
O	1469	1470	)
O	1470	1471	.

O	1472	1482	Pregabalin
O	1483	1486	did
O	1487	1490	not
O	1491	1497	reduce
B-outcome	1498	1508	persistent
I-outcome	1509	1513	pain
O	1514	1515	(
B-iv-bin-percent	1515	1517	60
I-iv-bin-percent	1517	1518	%
O	1519	1521	vs
B-cv-bin-percent	1522	1524	46
I-cv-bin-percent	1524	1525	%
O	1525	1526	;
O	1527	1535	relative
O	1536	1540	risk
O	1541	1542	=
O	1543	1544	1
O	1544	1545	.
O	1545	1546	3
O	1546	1547	;
O	1548	1550	95
O	1550	1551	%
O	1552	1562	confidence
O	1563	1571	interval
O	1572	1573	=
O	1574	1575	.
O	1575	1577	90
O	1577	1578	-
O	1578	1579	1
O	1579	1580	.
O	1580	1582	90
O	1582	1583	)
O	1584	1587	and
O	1588	1595	neither
O	1596	1606	pregabalin
O	1607	1610	nor
O	1611	1620	lidocaine
O	1621	1629	impacted
O	1630	1635	acute
O	1636	1649	postoperative
O	1650	1654	pain
O	1654	1655	,
O	1656	1662	opioid
O	1663	1674	consumption
O	1674	1675	,
O	1676	1680	pain
O	1681	1693	interference
O	1693	1694	,
O	1695	1697	or
O	1698	1705	quality
O	1706	1708	of
O	1709	1713	life
O	1713	1714	.

O	1715	1718	Our
O	1719	1724	pilot
O	1725	1730	trial
O	1731	1743	successfully
O	1744	1756	demonstrated
O	1757	1768	feasibility
O	1769	1772	and
O	1773	1781	provided
O	1782	1791	promising
O	1792	1796	data
O	1797	1800	for
O	1801	1811	conducting
O	1812	1819	further
O	1820	1826	trials
O	1827	1829	of
O	1830	1844	intraoperative
O	1845	1854	lidocaine
O	1855	1864	infusions
O	1865	1871	during
O	1872	1878	breast
O	1879	1885	cancer
O	1886	1895	surgeries
O	1895	1896	.

O	1897	1905	Clinical
O	1906	1911	trial
O	1912	1918	number
O	1918	1919	:
O	1920	1931	NCT02240199
O	1932	1943	PERSPECTIVE
O	1943	1944	:
O	1945	1949	This
O	1950	1957	article
O	1958	1965	reports
O	1966	1969	the
O	1970	1978	findings
O	1979	1981	of
O	1982	1983	a
O	1984	1989	pilot
O	1990	2000	randomized
O	2000	2001	,
O	2002	2012	controlled
O	2013	2018	trial
O	2019	2029	evaluating
O	2030	2033	the
O	2034	2041	effects
O	2042	2044	of
O	2045	2058	perioperative
O	2059	2069	pregabalin
O	2070	2073	and
O	2074	2088	intraoperative
O	2089	2098	lidocaine
O	2099	2108	infusions
O	2109	2111	in
O	2112	2120	patients
O	2121	2131	undergoing
O	2132	2138	breast
O	2139	2145	cancer
O	2146	2153	surgery
O	2153	2154	.

O	2155	2159	This
O	2160	2165	trial
O	2166	2178	demonstrated
O	2179	2182	the
O	2183	2194	feasibility
O	2195	2197	of
O	2198	2208	conducting
O	2209	2210	a
O	2211	2217	larger
O	2218	2223	trial
O	2224	2227	and
O	2228	2236	provided
O	2237	2246	promising
O	2247	2251	data
O	2252	2256	that
O	2257	2262	these
O	2263	2276	interventions
O	2277	2280	may
O	2281	2289	decrease
O	2290	2293	the
O	2294	2305	development
O	2306	2308	of
O	2309	2319	persistent
O	2320	2324	pain
O	2324	2325	.
